PAHC PHIBRO ANIMAL HEALTH CORP Insider Trading

Director E Thomas Corcoran buys 10,000 PAHC shares at $31.77; stock now $28.52, -52.5% from 52-week high

E Thomas Corcoran, a PAHC director, purchased 10,000 shares at $31.77 on 2026-05-29, increasing his holdings to 41,459 shares (a 31.8% increase). The transaction occurs against a backdrop of significant recent weakness: the stock trades at $28.52, down 52.5% from its 52-week high of $60.08 and down 48.0% over the past 30 days. Corcoran's prior two purchases at PAHC both posted positive 90-day returns (5.2% and 16.2%), suggesting his historical timing at this ticker has been favorable. The company's underlying fundamentals remain solid—revenue of $383.5M, net income of $24.0M, annual revenue growth of 27.4%, and a P/E of 20.67—yet the stock's sharp recent decline stands in stark contrast. This purchase represents an open-market commitment of capital during a period of substantial drawdown, though whether it reflects conviction or represents a discretionary tactical move cannot be determined from the transaction data alone.

CEO and 10% owner Jack Bendheim sells over $1M of PAHC shares across 7 transactions; all prior sales on this stock poorly timed as shares rose afterward.

Jack Bendheim, President, CEO, and 10% beneficial owner of Phibro Animal Health, divested over $1 million in shares across seven separate transactions over three trading days, reducing his holdings by roughly 18,600 shares. This marks his third major selling cycle in recent weeks—his two most recent sale batches just days earlier both saw the stock rise significantly afterward, a pattern consistent across all five of his prior sales on this ticker. The CEO is selling into strength: the stock trades near its recent highs and has staged a strong recovery over the past three months, making this timing notably different from his past sales, which typically preceded gains rather than pullbacks. Phibro remains a profitable, revenue-growing company, so this divestiture does not signal financial distress; rather, it represents a material reduction in Bendheim's personal exposure to a stock that has climbed substantially and at which he has been a net seller for months. Retail investors should note that concentrated insider selling—especially by a founder-aligned 10% owner—typically warrants closer examination, particularly when the seller's track record shows poor timing on similar exits.

PAHC President & CEO Bendheim sells 21,120 shares for $1,137,592.76 via 10b5-1 plan

BENDHEIM JACK, who was President and CEO at the time of filing, executed 7 separate sales totaling 21,120 shares for $1,137,592.76 between April 28–30, 2026, at prices ranging from $52.65 to $56.69. This transaction was conducted under a pre-arranged 10b5-1 trading plan, meaning the sales were scheduled and non-discretionary. The sales reduced his holdings from 95,880 shares to 74,760 shares, representing a 22.0% reduction in his post-transaction holdings. Because this activity is governed by a 10b5-1 plan rather than driven by contemporaneous market judgment, the transaction reflects execution of a pre-existing commitment rather than a signal of current market views.

BENDHEIM JACK sells 21,120 shares for $1,157,091.23 via pre-arranged 10b5-1 plan

BENDHEIM JACK, who was President and CEO at the time of filing, executed 5 separate sales totaling 21,120 shares for $1,157,091.23 on April 21–23, 2026, at prices ranging from $54.07 to $56.17 with a blended average of $54.79. This transaction reduced his holdings from 117,000 shares to 95,880 shares, a -18.1% net change. The sales were conducted pursuant to a pre-arranged 10b5-1 trading plan, meaning they were scheduled in advance rather than discretionary trades. As a scheduled transaction under a trading plan, this sale carries no implications regarding timing or conviction.

PAHC CEO Bendheim sold 21,120 shares over 3 days (Apr 14–16) for $1,201,595.13; holds 117,000 post-sale

Jack Bendheim, PAHC's President and CEO, executed 7 separate sales totaling 21,120 shares for $1,201,595.13 (blended average $56.89) across April 14–16, reducing holdings from 138,120 to 117,000 shares (-15.3%). The stock is currently at $53.88, down 9.6% from its 52-week high of $59.58, though up 31.2% over 90 days and 2.6% over 30 days. A FLAG indicates this filing involves a derivative-conversion transaction, meaning the Form 4 Table I holdings shown do not represent the insider's total position; derivative securities data (Table II) is not yet populated in the database. The company reports strong fundamentals (annual revenue growth of +27.4%, $373.9M latest-quarter revenue, $27.5M net income) but trades at a 40.21 P/E. His prior 5 sales at PAHC (late March 2026) are too recent to measure outcome, and none of his cross-ticker track record (20 prior sells, +1.3% average 30-day return) have yet demonstrated predictive timing at this specific ticker.

Jack Bendheim, then-CEO of PAHC, sold 14,080 shares for $756,833.69 under 10b5-1 plan

Jack Bendheim, who was CEO at the time, executed 4 separate sales totaling 14,080 shares for $756,833.69 on March 30-31, 2026, at blended average price $53.75. This represents a 27.0% reduction of his pre-transaction holdings (from 52,200 to 38,120 shares). The transaction is part of a pre-arranged 10b5-1 trading plan, so the sales were scheduled rather than discretionary. Since the FLAG indicates this is a scheduled plan, no timing inference should be drawn; the value lies in observing that substantial CEO equity has been liquidated even as the position remains material at 38.1K shares post-transaction.

Then-CEO Bendheim sold 21,120 shares for $1,166,104.52 across 7 transactions via scheduled 10b5-1 plan

Jack Bendheim, who was President and CEO at the time of filing, executed 7 separate sales totaling 21,120 shares for $1,166,104.52 across three trading days (March 24–26, 2026), at prices ranging from $52.88 to $57.17. The transaction was part of a pre-arranged 10b5-1 trading plan, meaning it was scheduled rather than discretionary. His post-transaction holdings of 52,200 shares represent a reduction of 28.8% from pre-transaction holdings of 73,320 shares. The structured, multi-day execution at incrementally rising prices reflects the mechanics of a scheduled divestiture plan rather than any single market timing decision.

PAHC CEO Bendheim sold 22,880 shares for $1.2M across 3 days; 5 prior sales at same ticker in Feb 2026

Jack Bendheim, President and CEO of Phibro Animal Health, executed 7 separate sales totaling 22,880 shares for $1,198,818.13 ($1.2M) at a blended average price of $52.40 across March 17–19, 2026, reducing his position by 23.8% from 96,200 to 73,320 shares. This sale follows a pattern of recent insider activity at the same ticker: Bendheim conducted 5 prior sells at PAHC on February 24–26, 2026, suggesting sustained capital allocation activity rather than a single discrete event. The company's fundamentals show strong growth (revenue up 27.4% year-over-year, $373.9M latest quarter) and profitability ($27.5M net income), though the stock trades at a P/E of 39.09 and is currently 4.2% below its 52-week high of $54.70. The transaction executed near the middle of the 52-week range and slightly above current price ($52.38), offering no clear timing signal relative to recent price momentum (90-day change +40.6%). Bendheim's cross-ticker track record shows 20 prior sells with an average 30-day return of -1.1%, but outcomes on his same-ticker PAHC sales from late February remain unmeasurable.

PAHC President and then-CEO BENDHEIM JACK sold 21,120 shares for $1.1M across 5 transactions (Feb 24-26)

BENDHEIM JACK, who was President and CEO at the time, executed 5 separate sales totaling 21,120 shares for $1,103,937.67 at prices ranging from $51.27 to $54.28, reducing his holdings from 22,600 shares to 1,480 shares. This transaction is part of a pre-arranged 10b5-1 trading plan, meaning the sales were scheduled rather than discretionary. The -93.5% reduction in his post-transaction holdings represents a substantial decrease in his direct ownership stake in PAHC. Investors should note that this was a scheduled liquidation, not a discretionary trade, and that BENDHEIM JACK is no longer the company's CEO per the most recent SEC filings.

PAHC: Bendheim (then-CEO) sold 14,080 shares via 10b5-1 plan for $715,775.01 on 2026-02-19/20

Jack Bendheim, who was President and CEO at the time of filing, executed three separate sales totaling 14,080 shares for $715,775.01 across February 19-20, 2026, reducing his holdings by 38.4% from 36,680 to 22,600 shares. The sales were conducted under a pre-arranged 10b5-1 trading plan, meaning execution was scheduled rather than discretionary. The blended average sale price of $50.84 across the three transactions reflects modest price movement ($50.26 to $51.96) during the two-day execution window. This represents a substantial reduction in his shareholding at Phibro Animal Health following his departure or transition from the CEO role, consistent with liquidity or portfolio adjustment by a departing executive.